Efficacy and safety of LY3537982, a potent and highly selective KRAS G12C inhibitor in KRAS G12C-mutant GI cancers: Results from a phase 1 study Meeting Abstract
| Authors: | Hollebecque, A.; Kuboki, Y.; Murciano-Goroff, Y. R.; Yaeger, R.; Cassier, P. A.; Heist, R. S.; Fujiwara, Y.; Deming, D. A.; Ammakkanavar, N.; Patnaik, A.; Shimizu, T.; Call, J.; Han, S. W.; Fink, A. A.; Chen, A.; Willard, M. D.; Balar, A. V.; Koyama, T. |
| Abstract Title: | Efficacy and safety of LY3537982, a potent and highly selective KRAS G12C inhibitor in KRAS G12C-mutant GI cancers: Results from a phase 1 study |
| Meeting Title: | 2024 ASCO Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 3 Suppl. |
| Meeting Dates: | 2024 Jan 18-20 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-01-20 |
| Language: | English |
| ACCESSION: | WOS:001266680500655 |
| DOI: | 10.1200/JCO.2024.42.3_suppl.94 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 94 -- Source: Wos |
